Q3 2018 13F Holders as of 30 Sep 2018
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
101.01%
-
Total 13F principal
-
$418,404,000
-
Principal change
-
+$49,840,000
-
Total reported market value
-
$422,410,019
-
Number of holders
-
44
-
Value change
-
+$54,142,363
-
Number of buys
-
18
-
Number of sells
-
19
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q3 2018
As of 30 Sep 2018,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
44 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$418,404,000
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, OAKTREE CAPITAL MANAGEMENT LP, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ADVENT CAPITAL MANAGEMENT /DE/, AMERIPRISE FINANCIAL INC, DLD Asset Management, LP, WOLVERINE ASSET MANAGEMENT LLC, MACKAY SHIELDS LLC, TENOR CAPITAL MANAGEMENT Co., L.P., and Graham Capital Management, L.P..
This page lists
44
institutional bondholders reporting positions
for the Q3 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.